KMDA

Kamada

KMDA, USA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

https://www.kamada.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KMDA
stock
KMDA

Precision Trading with Kamada Ltd. (KMDA) Risk Zones news.stocktradersdaily.com

Read more →
KMDA
stock
KMDA

Aug Ideas: How supply chain issues affect KMDA stock - Quarterly Performance Summary & Technical Confirmation Trade Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$14.75

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

19.14

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.56

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.00 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.40 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

14.52 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.42

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.58% of the total shares of Kamada

1.

ARK Israel Innovative Technology ETF

(0.4536%)

since

2025/08/28

2.

DFA International Small Company I

(0.3455%)

since

2025/07/31

3.

1290 Essex Small Cap Growth I

(0.1506%)

since

2025/07/31

4.

DFA International Core Equity 2 I

(0.1432%)

since

2025/07/31

5.

Pleiades Small Cap Equity A

(0.0816%)

since

2025/06/30

6.

Dimensional International Small Cap ETF

(0.0516%)

since

2025/08/29

7.

Fidelity Nasdaq Composite Index

(0.0511%)

since

2025/07/31

8.

Dimensional Global Trgtd Value USD Acc

(0.0451%)

since

2025/07/31

9.

Dimensional International Core Eq 2 ETF

(0.0401%)

since

2025/08/29

10.

Dimensional International Sm Cp Val ETF

(0.0382%)

since

2025/08/29

11.

Mandarine Global Microcap G EUR

(0.0286%)

since

2025/05/31

12.

Dimensional World ex US Core Eq 2 ETF

(0.028%)

since

2025/08/29

13.

DFA International Vector Equity I

(0.0233%)

since

2025/07/31

14.

Metis International Micro Cap Equity

(0.0217%)

since

2025/06/30

15.

DFA World ex US Core Equity Instl

(0.0155%)

since

2025/07/31

16.

Metis Global Micro Cap Equity

(0.0146%)

since

2025/06/30

17.

Brighthouse/Dimensional Intl Sm Cm A

(0.0138%)

since

2025/06/30

18.

DFA World ex US Targeted Val Instl

(0.0128%)

since

2025/06/30

19.

Gestión Boutique VIII River Global FI

(0.0107%)

since

2025/08/31

20.

Dimensional Global Small Coms USD Acc

(0.0104%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.1

Latest Release

Date

2025-09-30

EPS Actual

0.29

EPS Estimate

0.09

EPS Difference

0.2

Surprise Percent

222.2222%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(5)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(7)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.